Eli Lilly's Alzheimer's Drug Approved by FDA, Market Reaction Muted
TL;DR Summary
Eli Lilly's stock did not surge following the FDA approval of its Alzheimer's drug, Kisunla, because the approval was already anticipated and priced into the stock. Investors are more focused on the company's potential in the anti-obesity market with its GLP-1 treatments, which are expected to generate significantly higher revenue.
Topics:business#alzheimers-drug#businesshealthcare#eli-lilly#fda-approval#glp-1-treatments#stock-market
- Eli Lilly's Alzheimer's Drug Obtains FDA Approval. Here's Why the Stock Isn't Taking Off. Yahoo Finance
- Third FDA-approved Alzheimer’s drug can give patients more time with family The Spokesman Review
- The end of the beginning: Lilly execs eye top spot in burgeoning Alzheimer's market after Kisunla's FDA approval FiercePharma
- Is Eli Lilly Stock a No-Brainer Buy After Its FDA Alzheimer's Disease Drug Win? The Motley Fool
- Newly Approved Donanemab Brings Another Treatment Option for Alzheimer Disease: Joel Salinas, MD, MBA Neurology Live
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 4 min read
Condensed
93%
744 → 50 words
Want the full story? Read the original article
Read on Yahoo Finance